PHARM MANUF/DISTR DIV - FSA

The Defense Logistics Agency (DLA) plans to issue a national requirements contract solicitation for Sorafenib 200 MG Tablets packaged in 120-count bottles. This procurement will be unrestricted and fully competitive, structured as a firm-fixed price, requirements-type contract with a one-year base period and up to four one-year option periods. The contract aims to establish a national supply source in compliance with FAR 52.216-21, serving Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons through the DLA and VA prime vendor programs. Estimated annual usage will be detailed in the solicitation's Schedule of Supplies. Since Sorafenib is considered a commercial item, the acquisition will follow FAR part 12 procedures. The solicitation, numbered SPE2D2-25-R-0016, is managed by DLA Troop Support based in Philadelphia, PA, with an anticipated release around June 2025, though DLA may issue it sooner or later. All interested sources are encouraged to submit proposals, which will be reviewed by the agency. The solicitation will be accessible on the DLA Bid Board System (DIBBS) and SAM.gov, where vendors can also set up automated notifications for updates. Contact points for inquiries include Ryan Guarnere and Jason Wray at DLA. This contract falls under NAICS code 325412, manufacturing pharmaceuticals, and intends to ensure a reliable national supply of Sorafenib Tablets to various federal health agencies.